表紙
市場調查報告書
商品編碼
364846

纖維母細胞生長因子2:開發中產品分析

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 65 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以纖維母細胞生長因子2為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

纖維母細胞生長因子2概要

治療藥的開發

纖維母細胞生長因子2:開發中的產品 - 各開發階段

纖維母細胞生長因子2:開發中的產品 - 各治療範圍

纖維母細胞生長因子2:開發中的產品 - 各適應症

纖維母細胞生長因子2:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

纖維母細胞生長因子2:企業開發中的產品

纖維母細胞生長因子2:大學/機關開發中的產品

纖維母細胞生長因子2:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

纖維母細胞生長因子2治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Kringle Pharma, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Ohr Pharmaceutical Inc.
  • Progen Pharmaceuticals Limited
  • Ribomic Inc.

藥物簡介

纖維母細胞生長因子2:暫停中的計劃

纖維母細胞生長因子2:開發中止的產品

纖維母細胞生長因子2:主要消息和新聞稿

附錄

目錄
Product Code: GMDHC2987TDB

Summary:

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Infectious Disease, Metabolic Disorders, Ophthalmology, Central Nervous System, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Choroidal Neovascularization, Coronavirus Disease 2019 (COVID-19), Critical Limb Ischemia, Melanoma, Wet (Neovascular / Exudative) Macular Degeneration, Achondroplasia, Bone Disorders, Cancer Pain, Dengue Fever, Diabetic Foot Ulcers, Diabetic Macular Edema, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Intermittent Claudication, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Non-Small Cell Lung Cancer, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Artery Occlusive Disease (PAOD), Rheumatoid Arthritis, Solid Tumor and Venous Leg Ulcers (Crural Ulcer).

The latest report Fibroblast Growth Factor 2 - Drugs In Development, 2021, outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
  • Anaeropharma Science Inc
  • Aurealis Therapeutics AG
  • ID Pharma Co Ltd
  • Johnson & Johnson
  • RemeGen Co Ltd
  • Ribomic Inc
  • Zucero Therapeutics Ltd
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
  • AUP-16 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DVC-10101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate FGF2 for Critical Limb Ischemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • necuparanib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pixatimod - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RBM-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RC-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TR-764 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 30, 2021: RIBOMIC announces presentation of masked preliminary interim data from phase 2 trials of RBM-007 for wet age-related macular degeneration at the Retina Society 2021 Meeting
  • Aug 30, 2021: RIBOMIC completes patient enrollment of its US phase 2 open-label extension clinical trial of RBM-007 for wet age-related macular degeneration (RAMEN Study)
  • Aug 05, 2021: RIBOMIC completes patient enrollment of its US phase 2 clinical trial of RBM-007 for wet age-related macular degeneration (TOFU Study)
  • Jul 12, 2021: RIBOMIC announces first patient dosed in an investigator sponsored trial of RBM007 in treatment naive wet AMD patients
  • May 12, 2021: RIBOMIC announces completion of its phase I trial of RBM-007 for the treatment of achondroplasia
  • May 06, 2021: RIBOMIC announces publication of research paper on aptamer drug discovery for achondroplasia
  • Feb 01, 2021: Ribomic announces completion of 50% of enrollment of its phase 2 clinical trial for wet age-related macular degeneration (TOFU study)
  • Nov 11, 2020: RIBOMIC announces initiation of RAMEN open-label extension clinical trial for RBM007 in wet AMD patients
  • Jul 15, 2020: RIBOMIC announces dosing of first subject in RBM-007 phase 1 clinical trial for Achondroplasia
  • May 11, 2020: Safe-to-proceed under IND to initiate clinical trials of RBM-007 for treatment of achondroplasia
  • May 07, 2020: RIBOMIC resumes trial recruitment suspended by coronavirus
  • Apr 10, 2020: RIBOMIC announces completion of IND submission of RBM-007 for treatment of achondroplasia
  • Mar 24, 2020: RIBOMIC provides update on the status of its phase 2 clinical trial of RBM-007 (TOFU study) in subjects with wet age-related macular degeneration
  • Feb 25, 2020: RIBOMIC presented results of phase 1/2a clinical trial of RBM-007 (SUSHI) in subjects with wet age-related macular degeneration at two conferences
  • Feb 19, 2020: RIBOMIC announces first injection in the Phase 2 clinical trial of RBM-007 (TOFU Study) in subjects with wet age-related macular degeneration
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Anaeropharma Science Inc, 2021
  • Pipeline by Aurealis Therapeutics AG, 2021
  • Pipeline by ID Pharma Co Ltd, 2021
  • Pipeline by Johnson & Johnson, 2021
  • Pipeline by RemeGen Co Ltd, 2021
  • Pipeline by Ribomic Inc, 2021
  • Pipeline by Zucero Therapeutics Ltd, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021